The critical role played by CDK9 in facilitating RNA Pol II transcriptional elongation makes CDK9 inhibitors well suited for the treatment of cancers characterized by transcriptional dysregulation as a consequence of MYC amplification or MLL1 rearrangements [2, 28, 29]. This evidence concerns the gene KMT2A and cancer.